carcinoid syndrome

Lexicon announces publication of Telestar study results for Carcinoid Syndrome
news

NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES PUBLICATION OF TELESTAR STUDY RESULTS FOR TELOTRISTAT ETHYL IN THE JOURNAL OF CLINICAL ONCOLOGY Results from Pivotal Phase 3 Clinical Study of Telotristat Ethyl Show Clinical Benefit in Patients with Carcinoid Syndrome The Woodlands, Texas, October 31, 2016 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the Journal of Clinical Oncology published detailed results from Lexicon’s pivotal Phase 3 TELESTAR clinical study

Carcinoid Syndrome Impact Survey
advocacy

We are excited to participate in the Carcinoid Syndrome Impact Survey, which is designed to help better understand the impact that carcinoid syndrome has on patient lives, while also exploring physicians’ approaches to treating the disease. This survey is groundbreaking in that it brings together the collective efforts of leading national and regional patient advocacy groups: Carcinoid Cancer Foundation (CCF) Neuroendocrine Cancer Awareness Network (NCAN) Neuroendocrine Tumor Research Foundation (NETRF) The Healing